1.Evidence mapping analysis of clinical research on traditional Chinese medicine in treatment of vertigo.
Yan-Hua JIANG ; Zhen-Zhen QIAN ; Jian ZHU ; Guang WU ; Hong-Li WU ; Zhi-Wei JING
China Journal of Chinese Materia Medica 2023;48(18):5102-5112
In this study, the evidence map system was used to sort out the clinical research evidence on traditional Chinese medicine(TCM) treatment of vertigo and understand the evidence distribution in this field. CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, and Web of Science were searched for the clinical randomized controlled trial(RCT) and systematic reviews/Meta-analysis on TCM treatment of vertigo in recent five years, and the evidence was analyzed and presented in the form of text and charts. The Cochrane handbook for systematic reviews of interventions was used to evaluate the quality of the clinical RCT, and the AMSTAR mea-surement tool was used to evaluate the quality of the systematic reviews/Meta-analysis. A total of 382 RCTs and eight systematic reviews/Meta-analysis were included. In recent five years, the number of published articles has been on the rise. There were many intervention measures and TCM therapies for vertigo. Outcome indicators mainly included clinical efficacy, TCM syndrome score, vertigo score, occurrence of adverse reactions, and effective rate. The overall quality of clinical RCT and systematic reviews/Meta-analysis was low. Most studies have proven the potential efficacy of TCM in treating vertigo, but there was still no clear clinical evidence of efficacy. The results show that TCM has advantages in the treatment of vertigo, but there are also problems. More high-quality studies are still lacking, suggesting that more large-sample and multi-center RCT should be conducted in the future, and the quality of relevant syste-matic reviews/Meta-analysis should be improved to fully explore the advantages of TCM in the treatment of vertigo, and provide strong support for the effectiveness and safety of TCM in the treatment of vertigo.
Humans
;
Medicine, Chinese Traditional
;
Systematic Reviews as Topic
;
Treatment Outcome
;
Syndrome
;
Publications
;
Drugs, Chinese Herbal/therapeutic use*
2.Evidence mapping analysis of traditional Chinese medicine intervention in pulmonary fibrosis.
Wen-Yu SUN ; Xue-Qin ZHANG ; Yu-Jie GUO ; Hong-Yong DENG
China Journal of Chinese Materia Medica 2023;48(20):5641-5650
This study utilized evidence mapping methodology to systematically identify, describe, and evaluate the evidence from relevant research on traditional Chinese medicine(TCM) interventions in patients with pulmonary fibrosis. CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library were searched from database inception to March 2023 for systematic reviews/Meta-analysis/network Meta-analysis on TCM interventions in pulmonary fibrosis. The quality of included studies was assessed using the AMSTAR 2 scale, and the evidence mapping approach was employed to present comprehensive information on populations, intervention methods, the sample size in systematic reviews/Meta-analysis, and conclusion classifications. Ultimately, 44 systematic reviews/Meta-analysis/network Meta-analysis were included. Apart from syndrome differentiation and treatment, TCM injections accounted for a significant proportion of the observed interventions. The treatment methods were mainly focused on nourishing Qi and Yin, promoting blood circulation, resolving stasis, and dredging collaterals. The results from the included studies demonstrated that TCM treatment for pulmonary fibrosis could improve efficacy, increase lung function, improve PaO_(2 )levels, increase the 6-minute walk distance(6MWD), alleviate clinical symptoms, and enhance patients' quality of life. Based on the assessment using the AMSTAR 2 scale, methodological issues were identified, including the lack of protocol registration, failure to provide a list of excluded literature, and incomplete explanations regarding the impact of heterogeneity and bias on the results. The evidence mapping revealed that 42 conclusions were beneficial, while two conclusions were potentially beneficial. Overall, the quality of evidence was relatively low, primarily due to methodological imprecision and publication bias. Although TCM showed certain efficacy in the treatment of pulmonary fibrosis, the quality of reported literature, methodological quality, and overall evidence quality need improvement. It is recommended to conduct high-quality and standardized studies in the future to provide better evidence-based guidance.
Humans
;
Medicine, Chinese Traditional
;
Pulmonary Fibrosis/drug therapy*
;
Quality of Life
;
Systematic Reviews as Topic
;
Network Meta-Analysis
3.Overview of systematic reviews of Qingkailing Injection.
Ke-Lu YANG ; Yuan-Yuan LI ; Jin XIE ; Ya GAO ; Ming LIU ; Jin-Hui TIAN
China Journal of Chinese Materia Medica 2021;46(13):3446-3454
Qingkailing Injection is one of the most commonly used traditional Chinese medicine injections with significant clinical application for the treatment of multiple diseases. This study aims to analyze the systematic reviews( SRs) of Qingkailing Injection,in order to provide reference for the clinical application of Qingkailing Injection and the development of relevant clinical practice guidelines. We searched CNKI,CBM,Wanfang,VIP,Pub Med,Cochrane Library and EMbase to collect SRs from the time of database establishment to August 2020. The eligible SRs were included according to the inclusion and exclusion criteria. AMSTAR 2 was used to assess the methodological quality. The diseases,drugs in combinations and results were extracted and analyzed. A total of 24 SRs were selected,including 10 for the treatment of acute cerebrovascular diseases,9 for respiratory infections,2 for viral hepatitis,1 for chronic obstructive pulmonary disease,and two for the adverse effects of Qingkailing Injection. Only three entries of AMSTAR 2 item were fully reported by over 70%,and the rest were reported by less than 70%,with no report about item 2,3 and 10. Twenty-nine outcome indicators were correlated with the included SRs,of which three mostly frequent outcomes were effectiveness,adverse reaction,and neurological deficit scores,showing a good efficacy of Qingkailing Injection. The common severe adverse reaction was anaphylaxis,and mild adverse reactions were skin and mucous membrane reactions. The most frequently combined drug was antibiotics,mainly Penicillin and Penicillin+Pioneeromycin. The existing evidences showed that the methodological quality of SRs of Qingkailing Injection needed to be improved and Qingkailing Injection had an obvious efficacy. However,the selection of outcome indicators for clinical trials and SRs shall be standardized,and the reporting of basic information,such as drug combination,shall be strengthened to provide more powerful clinical services.
Drugs, Chinese Herbal/adverse effects*
;
Humans
;
Injections
;
Medicine, Chinese Traditional
;
Systematic Reviews as Topic
4.Introduction on 'assessing the risk of bias of individual studies' in systematic review of health-care intervention programs revised by the Agency for Healthcare Research and Quality.
J C YANG ; Z R YANG ; S Q YU ; S Y ZHAN ; F SUN
Chinese Journal of Epidemiology 2019;40(1):106-111
This paper summarizes the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions revised by the Agency for Healthcare Research and Quality (AHRQ) and introduces how to use Revman software make risk of bias graph or risk of bias summary. AHRQ tool can be used to evaluate following study designs: RCTs, cohort study, case-control study (including nested case-control), case series study and cross-sectional study. The tool evaluates the risk of bias of individual studies from selection bias, performance bias, attrition bias, detection bias and reporting bias. Each of the bias domains contains different items, and each item is available for the assessment of one or more study designs. It is worth noting that the appropriate items should be selected for evaluation different study designs instead of using all items to directly assess the risk of bias. AHRQ tool can be used to evaluate risk of bias individual studies when systematic reviews of health care interventions is including different study designs. Moreover, the tool items are relatively easy to understand and the assessment process is not complicated. AHRQ recommends the use of high, medium and low risk classification methods to assess the overall risk of bias of individual studies. However, AHRQ gives no recommendations on how to determine the overall bias grade. It is expected that future research will give corresponding recommendations.
Bias
;
Evidence-Based Medicine/standards*
;
Health Services Research
;
Systematic Reviews as Topic
5.Systematic Medicine And Composition Of Traditional Drugs
Amarzaya D ; Dagvatseren D ; Chimedragchaa Ch ; Purevjav L ; Tsend-Ayush D
Journal of Oriental Medicine 2015;9(2):31-35
Background
Module-hierarchical method of medicine preparation has been used
widely in traditional medicine for
the preparation of multi-compound medicine preparation.
Aim of study
This article aim to analyze traditional method of module-hierarchical
of medicine preparation in
prospect of theory and methodology of system as well as to
determine its form and nature.
Materials and methods
Relevant sections of the book “Four principals of medicine” was
used as a material in the research.
Research was done by using reference index calculation method
(Dagvatseren.B, 1996) that affects
humors of the medicine (wind, bile, phlegm). Identification of
diseases and the relationship between
medicines was analyzed in accordance with the systematic general
theory and methodology
(Urmantsev.Yu.A., 1988).
Results
There are 8 groups of medicines in the powder and herbal
medicines group of “Four principals of
medicine” that were prepared by module-hierarchic: 1) Dignitary
Gurgum-7, 2) Basic component
Gabur, 3) Anar-Basic component, 4) Anar-4 basic component, 5)
Dali-Basic component, 6)
Compound of Garanz-6, 7) Herbal medicine which expel fever with
a guide, 8) Herbal medicines
which eliminate cold. Total of 124 recipes and compounds are
included. .
Medicines prepared by module-hierarch are divided into: 1. Vertical
2. Horizontal 3.Beveled or
branched 4.Mixed type by its form of method.When calculating the
reference index of affecting the
mistakes of medicine of 124 medicines and compositions, reference
index of 119 medicines are in
accordance with their using instructions. But reference index of 5
recipes that were prepared by
leading and single taste exceeded the limit of 0:1.
Conclusions
Recipes and composition of medicines prepared by module-
hierarchic depends on relationship
between organs and system, its crisis (loss), disease progress and
classification.
It will keep the systematic characterestics of traditional medicine
and contains new independent
theoretical and methodological approach that can be named as
systematic traditional medicine,
treatment and research of systematic traditional medicine.
Systematic medicine
;
basic substances
;
disease location and classification
;
methods of compounding medicines made by module-hierarich
6.Evidence-based Chinese medicine:theory and practice.
Jun-Hua ZHANG ; You-Ping LI ; Bo-Li ZHANG
China Journal of Chinese Materia Medica 2018;43(1):1-7
The introduction and popularization of evidence-based medicine has opened up a new research field of clinical efficacy evaluation of traditional Chinese medicine(TCM), produced new research ideas and methods, and promoted the progress of clinical research of TCM. After about 20 years assiduous study and earnest practice, the evidence based evaluation method and technique, which conforms to the characteristics of TCM theory and practice, has been developing continuously. Evidence-based Chinese medicine (EBCM) has gradually formed and become an important branch of evidence-based medicine. The basic concept of evidence-based Chinese medicine: EBCM is an applied discipline, following the theory and methodology of evidence-based medicine, to collect, evaluate, produce, transform the evidence of effectiveness, safety and economy of TCM, to reveal the feature and regular pattern of TCM taking effect, and to guide the development of clinical guidelines, clinical pathways and health decisions. The effects and achievements of EBCM development: secondary studies mainly based on systematic review/Meta-analysis were extensively carried out; clinical efficacy studies mainly relying on randomized controlled trials grew rapidly; clinical safety evaluations based on real world study have been conducted; methodological researches mainly focused on study quality control deepened gradually; internationalization researches mainly on report specifications have got some breakthroughs; standardization researches based on treatment specification were strengthened gradually; the research team and talents with the characteristics of inter-disciplinary have been steadily increased. A number of high-quality research findings have been published at international well-known journals; the clinical efficacy and safety evidence of TCM has been increased; the level of clinical rational use of TCM has been improved; a large number of Chinese patent medicines with big market have been cultured. The future missions of EBCM mainly consist of four categories (scientific research, methodology and standard, platform construction and personnel training) with nine tasks. ①Carry out systematic reviews to systematically collect clinical trial reports of TCM and establish database of clinical evidence of TCM; ②Carry out evidence transformation research to lay the foundation for the development of clinical diagnosis and treatment guidelines, clinical pathways of TCM, and for the screening of basic drug list and medical insurance list, and for the policy-making relevant to TCM; ③Conduct researches to evaluate the advantages and effective regular patterns of TCM and form the evidence chain of TCM efficacy; ④Carry out researches for the safety evaluation of TCM, and provide evidence supporting the rational and safe use of TCM in clinical practice; ⑤Conduct researches on methodology of EBCM and provide method for developing high quality evidence; ⑥Carry out researches to develop standards and norms of TCM, and to form methods, standards, specifications and technical systems; ⑦Establish data management platform for evidence-based evaluation of TCM, and promote data sharing; ⑧Build international academic exchange platform to promote international cooperation and mutual recognition of EBCM research; ⑨Carry out education and popularization activities of evidence-based evaluation methods, and train undergraduate students, graduate students, clinical healthcare providers and practitioners of TCM. The development of EBCM, as it was, not only promoted the transformation of clinical research and decision-making mode of TCM, contributed to the modernization and internationalization of TCM, but also enriched the connotation of Evidence-based Medicine.
Biomedical Research
;
Evidence-Based Medicine
;
Humans
;
Medicine, Chinese Traditional
;
Meta-Analysis as Topic
;
Quality Control
;
Randomized Controlled Trials as Topic
;
Systematic Reviews as Topic
7.Evidence mapping of clinical research on prevention and treatment of essential hypertension with Chinese patent medicines in recent six years.
Li-Jie QIAO ; Bin LI ; Yong-Xia WANG ; Ming-Jun ZHU
China Journal of Chinese Materia Medica 2022;47(19):5375-5382
In this study, the evidence mapping was employed to systematically analyze the clinical research literature and learn the distribution of evidence on the prevention and treatment of essential hypertension with Chinese patent medicines in recent six years. CNKI, Wanfang, VIP, SinoMed, PubMed, and Cochrane Library were searched for the relevant literature published from January 2016 to December 2021. The distribution characteristics of evidence were analyzed and presented in charts combined with words. A total of 263 studies were selected, including 238 intervention studies, 17 systematic reviews/Meta-analysis, and 8 observation studies. A total of 72 Chinese patent medicines were involved, among which Songling Xuemaikang Capsules had the highest frequency. In China, the attention to the treatment of essential hypertension with Chinese patent medicines was insufficient, as manifested by the declining number of published literature and the low quality of studies. There were cases of off-label use and medication without syndrome differentiation in clinical practice. Some outcome indicators failed to embody the characteristics of traditional Chinese medicine and there were cases ignoring the end-point outcome indicators. The overall quality of systematic reviews/Meta-analysis was low, and a variety of studies failed to draw valid conclusions. In the future, it is necessary to standardize the clinical medication and improve the quality of randomized controlled trial(RCT), so as to produce high-quality evidence-based medical evidence and provide strong support for the efficacy and safety of Chinese patent medicines in the prevention and treatment of essential hypertension.
Humans
;
Asian People
;
Drugs, Chinese Herbal/therapeutic use*
;
Essential Hypertension/drug therapy*
;
Medicine, Chinese Traditional
;
Nonprescription Drugs/therapeutic use*
;
Systematic Reviews as Topic
;
Meta-Analysis as Topic
8.Critical quality evaluation and application value of network Meta-analyses in traditional Chinese medicine.
Yao CHEN ; Xue-Yang ZENG ; Di-Fei LIU ; Xiao-Yu TAN ; Xian-Ming CAI ; Feng-Wen YANG ; Xing LIAO ; Feng SUN ; Yan-Ming XIE
China Journal of Chinese Materia Medica 2019;44(24):5322-5328
To introduce the application status of network Meta-analysis( NMA) in the field of traditional Chinese medicine,and to discuss the application value of NMA in the field of traditional Chinese medicine,this study comprehensively reviewed the systematic reviews with application of NMA in the field of traditional Chinese medicine. CNKI,Wan Fang,Sino Med,VIP,Embase,PubMed and Cochrane Library and the reference list of previous studies were searched. The AMSTAR scale was used to evaluate the quality of literature methodology,and PRISMA-NMA checklist was used to measure the degree of report specification. Overall,122 articles were included,including 80 in Chinese and 42 in English. The included studies centered on cancer,bone and joint disease,cardiovascular disease,respiratory disease,mental disease and digestive disease. Additionally,the intervention can be categorized into three groups,traditional Chinese medicine injection,oral Chinese medicine or prescription,and traditional physical therapy including acupuncture.Nearly one-third of the researches' intervention program is aimed at comparing the effect of Chinese and Western combined therapy and monotherapy. The overall methodology quality grade is medium and the report quality is average,with methodology reporting and result reporting especially need to be improved. The subgroup analysis shows that the methodology quality of the English literatures is evidently higher than Chinese literatures,and the quality of the literatures published after 2015 is higher than those published in or before 2015.This study indicates that the NMA can compare multiple treatments simultaneously,which accords with characteristics of the clinical practice in traditional Chinese medicine that is complex and individual. NMA in the field of traditional Chinese medicine is still in the process of development. With higher level of quality control and reporting as well as the improvement of the statistical methodology and the accumulation of original researches,NMA application in the field of traditional Chinese medicine will be promising.
Administration, Oral
;
Humans
;
Injections
;
Medicine, Chinese Traditional
;
Network Meta-Analysis
;
Physical Therapy Modalities
;
Quality Control
;
Research Design/standards*
;
Systematic Reviews as Topic
9.Traditional Chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses.
Han-Ting WU ; Cong-Hua JI ; Rong-Chen DAI ; Pei-Jie HEI ; Juan LIANG ; Xia-Qiu WU ; Qiu-Shuang LI ; Jun-Chao YANG ; Wei MAO ; Qing GUO
Journal of Integrative Medicine 2022;20(5):416-426
BACKGROUND:
Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused an extensive burden to the world. Consequently, a large number of clinical trials have examined the efficacy of traditional Chinese medicine (TCM) for treating and preventing COVID-19, with coinciding proliferation of reviews summarizing these studies.
OBJECTIVE:
This study aimed to evaluate the methodological quality and evidence quality of systematic reviews and meta-analyses on the efficacy of TCM.
SEARCH STRATEGY:
Seven electronic databases, including PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Chongqing VIP, Wanfang Data and SinoMed, were searched for systematic reviews and meta-analyses in October 2021. Search terms such as "Chinese medicine," "Lianhua Qingwen" and "COVID-19" were used.
INCLUSION CRITERIA:
Systematic reviews and meta-analyses of randomized controlled trials that evaluated the efficacy of TCM treatment of COVID-19 were included.
DATA EXTRACTION AND ANALYSIS:
A Measurement Tool to Assess Systematic Reviews Version 2.0 (AMSTAR 2) was used to evaluate the methodological quality. The quality of evidence was graded using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Data extraction and analysis were performed by two reviewers independently.
RESULTS:
There were 17 meta-analyses included in our overview. The intervention group was defined as TCM combined with Western medicine, while the control group was Western medicine alone. The methodological quality of all the included studies was moderate to poor. A total of 89 outcome indicators were evaluated, of which, 8 were rated as moderate quality, 39 as low quality, and 41 as very low quality. Only one outcome measure was graded as being of high quality. The moderate quality of evidence indicated that, for the treatment of COVID-19, the clinical efficacy of TCM in combination with Western medicine was better, in terms of lung recovery, rate of conversion to severe/critical cases, symptom scores, duration of symptoms, mortality, and length of hospital stay.
CONCLUSION
Evidence from the included studies shows that, compared with conventional Western medical therapy alone, the addition of TCM to COVID-19 treatment may improve clinical outcomes. Overall, the quality of evidence of TCM for COVID-19 was moderate to poor. Meta-analyses of the use of TCM in the treatment of COVID-19 can be used for clinical decision making by accounting for the experiences of clinical experts, medical policies, and other factors.
COVID-19/drug therapy*
;
Drugs, Chinese Herbal/therapeutic use*
;
Humans
;
Medicine, Chinese Traditional
;
Meta-Analysis as Topic
;
Systematic Reviews as Topic
;
Treatment Outcome
10.Clinical practice guideline for postmenopausal osteoporosis with traditional Chinese medicine.
Yan-Ming XIE ; Huan LIU ; Jun-Jie JIANG ; Xu WEI ; Hao SHEN ; Ying-Jie ZHI ; Jing SUN ; Jin-Yu LI ; Xiao-Xia BAO ; Wei SHI ; Yi-Li ZHANG
China Journal of Chinese Materia Medica 2021;46(22):5992-5998
The editorial group of the clinical practice guideline for postmenopausal osteoporosis(PMOP) with traditional Chinese medicine(TCM)(hereinafter referred to as "guideline") is composed of experts specialized in TCM orthopedics, TCM gynecology, clinical epidemiology, etc. The guideline was formulated through registration, collection and selection of clinical issues/outcome indicators, evidence retrieval and screening, preparation of systematic reviews, evaluation of evidence quality, formation of recommendations, drafting, and peer review. The syndromes and treatment of PMOP are elaborated in detail. Specifically, Liuwei Dihuang Pills and Zuogui Pills are recommended for PMOP with Yin deficiency in the liver and kidney, Qing'e Pills for PMOP with kidney deficiency and blood stasis, Yougui Pills and Jingui Shenqi Pills for PMOP with Yang deficiency in the spleen and kidney, and Er'xian Decoction for PMOP with Yin and Yang deficiency in the kidney. In addition, Duhuo Jisheng Decoction can be used to relieve pain. The commonly used Chinese patent medicines include Xianling Gubao Capsules, Qianggu Capsules, Jintiange Capsules, Gushukang Capsules, Hugu Capsules, Jinwu Gutong Capsules, and Guyuling Capsules. Acupuncture and moxibustion are also effective approaches for PMOP. The rehabilitation and daily management were carried out by exercise therapies such as Baduanjin(eight-section brocade), Wuqinxi(five-animal exercises), and Taijiquan(Tai Chi), Chinese medicine diet, health education, and fall prevention. The promotion and application of this guideline will facilitate the implementation of TCM prevention and treatment of PMOP, ensure the quality of life of PMOP patients, provide effective and safe TCM treatment measures for PMOP, and reduce the risk of fracture complications.
Animals
;
Drugs, Chinese Herbal/therapeutic use*
;
Female
;
Humans
;
Medicine, Chinese Traditional
;
Osteoporosis, Postmenopausal/drug therapy*
;
Quality of Life
;
Systematic Reviews as Topic
;
Yin Deficiency